CytomX Therapeutics
Clinical trials sponsored by CytomX Therapeutics, explained in plain language.
A biotechnology company developing conditionally activated antibody therapeutics for cancer and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug combo takes on tough tumors
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called CX-801, alone or with the immunotherapy Keytruda, in 121 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will…
Phase 1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers? early trial launches
Disease control Recruiting nowThis first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumo…
Phase 1 • Sponsor: CytomX Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC